Onyx Pharmaceuticals Inc.'s new multiple myeloma drug Kyprolis (carfilzomib) will get a $358.6 million boost following a new public offering of stock from the South San Francisco-based company.
Versartis Inc., of Redwood City, Calif., closed a $25 million Series C financing round through Aisling Capital, Index Ventures, New Leaf Venture Partners and Advent Venture Partners to support clinical trials of VRS-317 for growth hormone deficiency in children.
Oculus Innovative Sciences Inc., of Petaluma, Calif., spun out a new biotechnology business to develop a drug candidate for infection in trauma and surgical procedures.
Morphotek Inc.'s promising ovarian cancer drug farletuzumab yielded disappointing results in a Phase III trial in ovarian cancer. The study, which combined farletuzumab with carboplatin and taxane in platinum-sensitive epithelial ovarian cancer, did not meet its primary endpoint of progression-free survival (PFS).
BIND Biosciences Inc., of Cambridge, Mass., signed a deal with Amgen Inc., of Thousand Oaks, Calif., worth up to $180.5 million. to collaborate on development of a nanotechnology-based therapeutic for solid tumors.
Peregrine Pharmaceuticals Inc.'s internal review of vial coding discrepancies from a Phase II trial of bavituximab in non-small-cell lung cancer (NSCLC) showed that the errors were isolated to placebo and 1-mg/kg treatment arms, leaving the 3-mg/kg treatment arm unaffected.
Vivus Inc. shared details of its launch plans and risk evaluation and management strategy (REMS) for newly approved weight loss drug Qsymia (phentermine/topiramate) on an investor call Wednesday morning. Vivus is aiming for a fourth-quarter launch with a REMS that includes a medication guide delivered with each prescription, a health provider training program and distribution of the drug through certified pharmacies only.
Updated regulations by the U.S. Small Business Administration (SBA) regarding the size and eligibility for Small Business Innovation Research (SBIR) and Small Business Technology Transfer programs may make the programs significantly more competitive when they take effect Jan. 28.
